BMO Capital Maintains Outperform on Pfizer, Lowers Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman has maintained an 'Outperform' rating on Pfizer (NYSE:PFE) but lowered the price target from $44 to $33.
October 16, 2023 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's price target has been lowered from $44 to $33 by BMO Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by BMO Capital indicates a potential decrease in Pfizer's stock price in the short term. However, the maintained 'Outperform' rating suggests that the analyst still sees potential for the stock to outperform the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100